UPDATE 3-U.S. regulators reject Sanofi's MS treatment Lemtrada

* Drug's prospects were at heart of $20 bln Genzyme takeover

from Reuters: Hot Stocks http://feeds.reuters.com/~r/reuters/hotStocksNews/~3/dp2VzgKYgak/story01.htm